CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED ͩᖹණྠϞࠢʮ̡

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

JMT601 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that JMT601 (CPO107), a first-in-class drug candidate developed by Shanghai JMT-BIO Technology Co., Ltd.*€ɪऎݵਟत͛ي ߅ҦϞࠢʮ̡, a subsidiary of the Company, has obtained approval of its investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA) to initiate clinical trial for advanced Non-Hodgkin lymphoma (NHL).

Non-Hodgkin lymphoma is a heterogeneous group of lymphoproliferative disorders originating from B-cell lymphocytes, T-cell lymphocytes or NK cells. While most patients with indolent NHL can live 20 years after diagnosis, the prognosis of those with aggressive lymphoma may worsen with overall five-year survival rate of around 60%. B-cell lymphoma with CD20 expression makes up most of NHL.

JMT601 (CPO107) is the world's first bispecific SIRPα fusion protein with synergised target binding effect which has entered clinical stage, it is a novel and rationally designed bispecific fusion protein based on the approved anti-CD20 antibody Ofatumumab by addition of a CD47 binding fragment SIRPα. It effectively binds to CD20 on the tumor cell surface to induce the antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Its subsequent synergised binding to CD47 expressed on the tumor cells serves as a "don't eat me" signal to the macrophages. JMT601 (CPO107)'s performance on blocking the interaction of CD47 with SIRPα expressed on the macrophages is significantly better as compared with SIRPα-Fc fusion protein. By disrupting the CD47/SIRPα interaction, JMT601 (CPO107) has enhanced antibody-dependent cellular phagocytosis activity (ADCP). Its enhanced efficacy as compared with conventional CD20-targeting antibodies was demonstrated in various human B-cell lymphoma models. The nonclinicaltoxicology studies conducted indicated that JMT601 (CPO107) has no obvious binding with CD20-negative cells and no significant suppression of strong CD47-positive cells including erythrocytes and thrombocytes was found at a dose of 100mpk, demonstrating the satisfactory safety profile and supporting the evaluation of JMT601 (CPO107) in clinical studies.

The approved study is a Phase 1/2, multicenter, first-in-human, dose escalation and dose expansion study to assess safety, pharmacokinetics and preliminary efficacy. The Group is also conducting a Phase I clinical study in China. Clinical data from these studies will guide further development of JMT601 (CPO107) for the treatment of Non-Hodgkin lymphoma and other hematological malignancies.

The Group will endeavor to push forward the clinical trials and strive to launch the product as soon as possible.

By Order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 29 March 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

*

For identification purpose only